• The Great Place to Work organization included MINDCURE in its 2021 list of the Best Workplaces Managed by Women
• The company was recognized for its employee-oriented perks and programs, which include flexible working hours, monthly team-building events, and a remote work office stipend
• MINDCURE also participated in the Life Sciences Virtual Investor Conference held on December 16, where executives shared the company’s corporate vision and fielded questions from investors and other attendees

Multiple studies have evidenced that women-led companies tend to perform better and are more likely to have more engaged, inspired, and satisfied employees than male-led firms. A Forbes article summarizing the findings of several of these studies concluded that having more females in executive roles is not only fair, but it is also good for business and employees (https://ibn.fm/lgbXc).

The veracity of this conclusion was on display recently when the Great Place to Work(TM), a global authority on building, maintaining, and recognizing high-trust, high-performance workplace culture by leveraging 30 years of research, announced Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (“MINDCURE”) as one of the Best Workplaces Managed by Women in 2021 (https://ibn.fm/AyxqJ).

To be eligible, companies must have been Great Place to Work-certified and have a female President and CEO. The Great Place to Work then determined the best companies based on employee responses to its Trust Index Survey.

Helmed by Co-Founder, President and CEO Kelsey Ramsden, MINDCURE was recognized for several of its perks and programs. These include flexible working hours that allow employees to improve their mental and physical well-being, monthly team-building events, and a remote work office stipend that assisted employees in setting up a home office. 

Headquartered in Vancouver, British Columbia, MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. It comes as no surprise, therefore, that this focus on mental health reflects in the company’s internal operations as seen in the company’s documented perks and programs.

In addition to researching psychedelic compounds, which has resulted in the production of synthetic ibogaine, MINDCURE also focuses on developing digital therapeutics (“DTx”) and is, in fact, a member of the Digital Therapeutics Alliance (“DTA”). 

Elsewhere, MINDCURE participated in the most recent Life Sciences Virtual Investor Conference, a day-long virtual, quarterly event that provides an efficient and unique opportunity for public and private companies to engage with a broader investor base and communicate their strategies. 

Held on December 16, the event featured live company presentations and interactive discussions. As part of its 30-minute presentation, MINDCURE executives shared the company’s corporate vision and responded to investors’ and other attendees’ questions (https://ibn.fm/F8PJA).

Notably, MINDCURE is ideally poised as an attractive investment option for investors interested in investing in psychedelics. This is partly because the company is focused on revolutionizing the mental health industry by researching and developing solutions that prioritize the root causes of mental health issues instead of the conventional symptoms-oriented remedy approach. As such, investors can participate in this revolution as well as propel it forward.

So far, the company has begun the production of synthetic ibogaine, a chemically complex psychedelic compound naturally found in plants native to West Africa. Preliminary data demonstrates that ibogaine can be used as a potential treatment for addiction, anxiety disorders and depression, and cognitive enhancement (https://ibn.fm/Pgcxw). Individually, these treatment areas represent significant market opportunities. 

For instance, the global drug addiction treatment market, which was valued at US$16.47 billion in 2018, is projected to grow at a 7.0% CAGR, reaching US$31.17 billion by 2027 (https://ibn.fm/Nt59D). The anxiety disorders and depression treatment market is projected to expand at a 2.6% CAGR from US$8.5 billion in 2019 to US$13.03 billion by 2027 (https://ibn.fm/YePRl). In addition, researchers at Allied Market Research anticipate that the global cognitive and memory enhancer drugs market will reach $6.6 billion by 2023 from $3.7 billion in 2016, marking a CAGR of 8.6% (https://ibn.fm/UTqM7).

Separately, the global DTx market is expected to reach US$13.1 billion by 2026 from US$3.4 billion in 2021, representing a CAGR of 31.4% (https://ibn.fm/ws6FD).

To uniquely capitalize on this projected growth, MINDCURE has striven to protect its innovations with provisional patent applications submitted for research and technological advances, as well as maintain a strong financial position.

For more information, visit the company’s website at www.MindCure.com.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.